AbbVie (ABBV)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
$288.24-2.24%
Close 2026-11-05 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
QuarterlyIQ Insights · ABBV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 14.5% |
| Our one-year growth estimate | diamond | 10.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 4.5 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 10 industry peers · Company calendar date is not available
ABBV — CEO transition
Dated 2026-11-02
Director — Jennifer L. Davis: A Class II director resigned to become CEO of another company, representing a genuine loss of a board member but not a C-suite executive departure.
Why it matters: Oncology sales fell in Q2, then grew just 0.8% in Q3. A return to stronger growth would ease that pressure.
Watch forQ4 oncology sales grow at least 5% year over year.
Also watch forQ4 oncology sales fall year over year, with Imbruvica sales down at least 20%.
Why it matters: The Phase 3 study met its main goal at week 16. Longer-term results may support a planned filing.
Supportive ifAbbVie reports that the 36-week results support the week-16 response, with no new safety concern.
Worry ifThe 36-week results show less benefit or a new safety concern. AbbVie delays the planned second-half 2027 filing.
Why it matters: Q3 Botox Cosmetic grew, but Juvederm fell. Their next results can show if the split continues.
Watch forIn a 2027 quarter, Botox Cosmetic growth is above 5%, and Juvederm sales stop falling year over year.
Also watch forA 2027 quarter shows both products down year over year, with Juvederm down at least 10%.
Why it matters: These drugs are key parts of AbbVie’s growth plan. Their Q3 sales rose from Q2.
Supportive ifQ4 Skyrizi sales grow year over year by at least 20%, and Rinvoq sales grow by at least 20%.
Worry ifEither drug's Q4 sales growth falls below 10% year over year.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$89 on $10,000 · ±0.9% | How much price usually moves either way. |
| Bad day | $237 loss on $10,000 · 2.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,574 loss on $10,000 · 15.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.